View Older Stories View More Recent Stories
-
Bernstein SocGen Group Starts Biogen (BIIB) at Market Perform
-
Biogen (BIIB) PT Lowered to $206 at Cantor Fitzgerald
-
Biogen (BIIB) Issues Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
-
Sage Therapeutics (SAGE) Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogen’s (BIIB) Unsolicited Acquisition Proposal
-
SAGE Therapeutics (SAGE) Explores Strategic Alternatives
-
FDA Approves Eisai and Biogen's LEQEMBI IV Maintenance Dosing for Treatment of Early Alzheimer’s Disease
-
Biogen (BIIB): FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
-
Biogen (BIIB) makes cuts across its research unit, shifting focus to ‘external opportunities’ - endpoints
-
Oppenheimer Reiterates Outperform Rating on Biogen (BIIB)
-
Biogen (BIIB) Appoints Sean Godbout as Chief Accounting Officer & Global Corporate Controller
-
SAGE Therapeutics (SAGE) Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen (BIIB) (earlier)
-
Biogen (BIIB) PT Lowered to $231 as RBC Capital Sees 'Attractive Entry Point for Shares'
-
Piper Sandler Downgrades Biogen (BIIB) to Neutral
-
Halozyme (HALO) Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo® (nivolumab) Indications
-
BMO Capital Downgrades Biogen (BIIB) to Market Perform
-
RBC Capital's Game Changers: 'Disruptive Forces in Biotech'
-
Stifel Downgrades Biogen (BIIB) to Hold
-
Truist: 'Potential Impact of Trump's Nominees on Biopharma'
-
Jefferies Downgrades Biogen (BIIB) to Hold
-
Biogen (BIIB) call put ratio 2.4 calls to 1 put with focus on 1300 contracts of December 185 calls
-
Needham Downgrades Biogen (BIIB) to Hold, 'Expert Checks Suggest Slow Leqembi Ramp; Limited 2025 Catalysts'
-
Samsung Bioepis and Biogen (BIIB) Receive EU Approval for OPUVIZ
-
Biogen (BIIB) PT Raised to $300 at Baird
-
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
-
Biogen (BIIB) and Eisai Receive Positive CHMP Opinion in the EU for Lecanemab in Early Alzheimer’s Disease
-
EMA says Leqembi recommended for treatment of early Alzheimer’s disease
-
Citi Starts Biogen (BIIB) at Neutral
-
Biogen (BIIB) PT Lowered to $275 at TD Cowen
-
Biogen (BIIB) PT Lowered to $255 at Oppenheimer
-
Biogen (BIIB) PT Lowered to $260 at RBC Capital
-
Morgan Stanley Downgrades Biogen (BIIB) to Equalweight
-
Biogen (BIIB) PT Raised to $315 at Piper Sandler
-
Goldman Sachs Reiterates Buy Rating on Biogen (BIIB)
-
Biogen (BIIB) Tops Q3 EPS by 31c; raises guidance
-
Stocks expected to have increasing option volume: BIIB FPN EAT MDLZ CMG EA FSLR SNAP CZR QRVO CAKE BAC FHN
-
Biogen (BIIB) Appoints Daniel Quirk, MD, as Chief Medical Officer
-
Truist Securities Reiterates Buy Rating on Biogen (BIIB)
-
Biogen (BIIB) Announces CFO Retirement
-
BMO Capital Reiterates Outperform Rating on Biogen (BIIB)
-
Biogen's (BIIB) Tecfidera Patent Upheld at European Patent Office - Bloomberg
-
Biogen (BIIB) Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024
-
Raymond James Resumes Biogen (BIIB) at Market Perform
-
Biogen (BIIB) Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
-
Biogen (BIIB): New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA
-
RBC makes changes to its Top 30 Global Ideas for 2024
-
SAGE Therapeutics (SAGE) Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 Program
-
BMO Capital Reiterates Outperform Rating on Biogen (BIIB)
-
Baird Reiterates Outperform Rating on Biogen (BIIB)
-
TD Cowen Reiterates Buy Rating on Biogen (BIIB)
-
Biogen (BIIB) and UCB Report Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus
